Replies to post #83720 on Langlui's Big Board and Options Plays

[Live42Day]

CXM bid stacking here @ .61. Bottom is in.

Good post on CXM's potential w/Excellarate (see how this stacks up against the only other competitor):

Regranex Topical Gel - currently the only FDA-approved advanced care biologic topical agent for the treatment of patients with lower extremity neuropathic diabetic foot ulcers.

Excellarate is a collagen-based topical gel employing TRC's Gene Activated Matrix™ (GAM) technology to stimulate a patient's cells to produce a sustained micro-release of platelet-derived growth factor-B (PDGF-B) protein directly within the patient's wound where it is needed. TRC’s Gene Activated Matrix (GAM)technology provides a therapeutic level of protein synthesis at the site of tissue injury and has potential utility in several clinical indications where protein therapeutics have had limited success, including the treatment of dermal wounds (diabetic ulcers, venous stasis ulcers), therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease), and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon and cartilage).

Regranex is patient administered, requires daily application followed by a daily cleansing 12 hours after the drug treatment over a 20-week period. As a result, during the prescribed 20-week treatment period, Regranex patients are required to undertake approximately 280 interventions (drug administrations and cleansings) to achieve the potential maximum healing effect.

Excellarate requires one or two physician administered treatment regimen.

Regranex - 50% of patients achieved complete wound closure in 20 weeks.

Excellarate - 83% of patients achieved complete wound closure in 14 weeks.

Regranex - Increase cancer risk in Patients

Excellarate - appears to be both safe and well tolerated, with no serious adverse events attributable to the study product.

The wound care market is projected to experience double digit growth over the next 3 to 5 years, with advanced wound care products comprising the fastest growing segment of the total wound care market. There are an estimated 91.3 million wounds in the U.S., which include 67.0 million surgical wounds, 17.6 million trauma wounds including burn injuries and amputations, 2.5 million pressure ulcers, 3.6 million diabetic ulcers and 3.3 million venous stasis and arterial ulcers. The ability to effectively address even a small proportion of these wounds would represent major new market opportunities for the Company's Gene Activated Matrix (GAM) technology.

In other words Excellerate will be the Number 1 topical gel for wound care which equals
PROFITS!!